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Abstract
Background: To examine the effectiveness and acceptability of an 8-week individual tailored cognitive behavioural
therapy (CBT) intervention for the treatment of depressive symptoms in those newly diagnosed with multiple
sclerosis.
Methods: The current study presents a pilot, parallel group randomized controlled trial (RCT) with an allocation
ratio of 1:1 conducted in a large research and teaching hospital in Melbourne, Australia. 30 individuals with a mean
age of 36.93 years (SD = 9.63) who were newly diagnosed with multiple sclerosis (MS) (X = 24.87 months, SD = 15.
61) were randomized to the CBT intervention (n = 15) or treatment as usual (TAU) (n = 15). The primary outcome
was level of depressive symptoms using the Beck Depression Inventory-II (BDI-II). Secondary outcomes were level of
anxiety, fatigue and pain impact, sleep quality, coping, acceptance of MS illness, MS related quality of life, social
support, and resilience. Tertiary outcomes were acceptability and adherence to the intervention.
Results: Large between group treatment effects were found for level of depressive symptoms at post and at
20 weeks follow-up (d = 1.66–1.34). There were also small to large group treatment effects for level of anxiety,
fatigue and pain impact, sleep quality, MS related quality of life, resilience, and social support at post and at
20 weeks follow-up (d = 0.17–1.63). There were no drop-outs and participants completed all treatment modules. All
participants reported the treatment as ‘very useful’, and most (73.4%) reported that the intervention had addressed
their problems ‘completely’.
Conclusions: These data suggest that the tailored early intervention is appropriate and clinically effective for the
treatment of depressive symptoms in those newly diagnosed with MS. A larger RCT comparing the CBT
intervention with an active comparative treatment with longer term follow-up and cost effectiveness analyses is
warranted. The pilot trial has been retrospectively registered on 28/04/2016 with the ISRCTN registry (trial ID
ISRCTN10423371).
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Background
Multiple sclerosis (MS) is the most common neuro-
logical disorder in young adults. It is estimated that 2.5
million people are living with MS worldwide. Diagnosis
of MS is typically between 20 and 40 years of age, three
quarters of whom are female [1]. MS has a range of con-
sequences on mental health. Depression and anxiety
have been found to be common in individuals with MS
and have been reported to be at clinically high levels es-
pecially in the early stages of the illness [2–4]. The life-
time prevalence of depression among individuals with
MS has been found to be 50% [5] and point prevalence
rates range from 15 to 26% [6]. Similarly, anxiety affects
between 16 and 45% of the MS population [7, 8] and has
been associated with younger age of onset, disease sever-
ity, fatigue [9] and severity of depressive symptoms [10].
Two studies suggest that up to 36% of MS patients con-
tinue to have high levels of depressive and anxiety symp-
toms in the first years after diagnosis [3, 11].
CBT for the treatment of depression in people diag-
nosed with MS have demonstrated significant reductions
in depression. A review of seven CBT studies (individual
(3 studies), group (3 studies) and by computer (1 study))
found a medium treatment effect of 0.5 SD [12]. One
study compared individual CBT with sertraline and
group therapy and found that those in the CBT and the
sertraline groups showed greater improvements in their
levels of depression compared to those in group therapy.
In addition, those in the individual CBT group displayed
improvements in mood, coping, and suicidal ideas [13].
Askey-Jones, David, Silber, Shaw and Chalder (2013)
[14] also examined the effectiveness of a CBT delivered
intervention and found that CBT resulted in statistically
significant decreases in depression and anxiety with large
effect sizes. More recently, Fischer et al., (2015) [15]
conducted a RCT comparing a CBT based online inter-
vention with a waitlist control group for the treatment
of depression in a sample of 71 outpatients who were di-
agnosed with MS for a mean length of 8 years. The re-
searchers found that those who completed the 9-week
online CBT program reported lower BDI-II scores at
post and 6 months follow up compared to those in a
waitlist control group.
To date, there are no published studies of early
provision of tailored CBT for the treatment of depres-
sion in the first five years of a MS diagnosis with inter-
ventions focused on those with established disease
(greater than 8 years). There are good reasons for early
provision of CBT for the treatment of depression in
those newly diagnosed with MS. Firstly, the time around
receiving a MS diagnosis has been shown to be when in-
dividuals experience significantly higher levels of depres-
sion and anxiety [2, 4, 11, 16]. Two studies suggest that
up to 36% of MS patients continue to have high levels of
depressive and anxiety symptoms in the first two years
after a diagnosis [11] and are at greater risk of suicide
[17]. Psychological factors are likely to be contributing.
For example, MS is diagnosed at a time point when indi-
viduals are typically establishing careers, relationships
and families. Individuals may also be adapting to the MS
diagnosis and symptoms, the burden of uncertainty and
dealing with the loss of physical and cognitive function-
ing, changes in interpersonal relationships, social and
work roles and social support and a reduction in posi-
tively reinforcing activities. Secondly, if left untreated de-
pression will worsen and contribute to further
deterioration having an impact on the course of MS [18]
resulting in exacerbation of MS relapses [19] and con-
tribute to higher suicide rates [5]. Treating depression
with CBT can contribute to the alteration of disease out-
comes. For example, depression has been found to be re-
lated to neurological changes in the brain due to the
demyelination process [20], treatment adherence to
medical advice and treatments [21], immune functioning
[22] and MS disease exacerbation [23]. Therefore, early
provision of treatment of depression may lead to im-
provements in adherence with possible positive impacts
on disease processes i.e., potentially reduce exacerba-
tions and influence longer term MS progression via in-
creased treatment adherence and reduce markers of MS
inflammation and deterioration [24]. Thirdly, studies
have demonstrated that early recognition and treatment
of depression can improve social function, increase
productivity and decrease absenteeism in the workplace
[25]. At the social level, early intervention has been sup-
ported because the longer a person remains depressed
the more strained the interpersonal and occupational
roles may become.
An intervention at the time of first diagnosis, with the
potential to modify the trajectory of psychological mor-
bidity, has not been explored. In light of the burden of
depression in the early stages of disease, the aims of the
study were to assess the efficacy of a tailored 8-week in-
dividualized CBT intervention in the treatment of de-
pressive symptoms (primary outcome) in individuals
who are within five years of a MS diagnosis. Secondary
aims were to examine improvements in levels of anxiety,
fatigue, pain, sleep quality, quality of life, coping, MS ill-
ness acceptance and resilience (secondary outcomes) at
post and 20 week follow up time points and evaluate sat-




This study was a 2-group RCT with an allocation ratio
of 1: 1: (1) Tailored CBT intervention (n = 15); and (2)
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TAU (n = 15). All participants completed questionnaires
at pre- and post-treatment and at 20 weeks follow up.
Participants
Eligibility criteria
Inclusion criteria were: 1) having a definite diagnosis of
MS from a neurologist; 2) being within 5 years of receiv-
ing a diagnosis of MS; 3) scoring at least 10 on the Beck
Depression Inventory-II (BDI-II) [26]; 4) not currently
undertaking other psychological treatment for depressive
or anxiety symptoms for the length of participation in
the current trial; 5) speak English fluently; 6) no current
or lifetime diagnosis of psychosis; 7) no current sub-
stance dependency; 8) no gross cognitive impairment;
and 9) no changes to medications prior and during in-
volvement in the trial.
Recruitment
The study took place at a large teaching and research
hospital in Melbourne, Australia. Participants were re-
cruited through neurologists working in a large MS out-
patient clinic at the hospital, advertisements on MS
related websites and local press releases. All participants
responded positively to two screening questions for de-
pressive symptoms. Participants were recruited from Oc-
tober 2013 to December 2014. The study was approved
by the Melbourne Health ethics committee. Figure 1
outlines the flow of participants through the trial and
reasons for ineligibility. Forty-seven people were
approached and screened and took part in the study. 17
of the 47 screened were not eligible for the trial giving a
participation rate of 64%. Fifteen participants were ran-
domly allocated to the CBT group and 15 to the TAU
control group. There were no drop outs. All participants
completed the pre, post and 20 week follow up question-
naires. Follow up assessments ended April, 2015. The
trial was stopped after achieving a total number of 30
participants (15 in each group).
Randomization and allocation concealment
Participants were randomly assigned using a computer
generated random numbers table using an allocation ra-
tio of 1: 1 to 1 of the 2 treatment groups. The allocation
sequence was concealed from the clinician enrolling and
assessing participants in opaque, sealed envelopes that
were numbered in advance and opened sequentially. All
Screened (n = 47)
Assessed for eligibility 
criteria and accepted
(n=30)
Did not fulfill eligibility 
criteria and excluded (n=17)
Lives in rural area (n=6)
No confirmed MS diagnosis 
(n=3)
Cognitive impairment (n = 1)
No depression (n = 2)
Did not return calls/email (n=5)
Randomised (n=30)








8 week follow up 
returned (n=15)
Lost to follow up 
(n=0)
8 week follow up 
returned (n=15)








20 week follow up 
returned (n=15)
Lost to follow up 
(n=0)
20 week follow up 
returned (n=15)










Participants referred to study 
and screened between October, 
2013 and December, 2014
Fig. 1 CONSORT flow chart of participants going through the trial
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clinicians were blind to the group allocation sequence.
The assignment to the CBT intervention or TAU group
schedule was locked away in a locked filing cabinet at
the hospital. Blinding of staff and participants after as-
signment to interventions was not maintained. Clinicians
who delivered the intervention were also involved in
providing the assessment questionnaires to participants.
Sample size calculation
A sample size of 30 was selected as this number has
been recommended for pilot studies [27].
Procedure
Pre-treatment assessment
Consenting and eligible participants were invited to
undertake a clinical interview at baseline with a clinical
psychologist at the hospital. One female senior clinical
psychologist and one male provisional clinical psycholo-
gist undertook assessments. During this baseline inter-
view, the goals and procedures were explained in detail
and written consent was obtained from all participants.
The Structured Clinical Interview of Disorders- Research
version (SCID-I/P) [28] was used to screen out patients
with psychotic disorders and substance dependency. Par-
ticipants who were eligible were asked to complete a
battery of questionnaires.
Tailored CBT intervention
The aim of the 8-week tailored intervention is to signifi-
cantly decrease level of depressive symptoms (primary
outcome), anxiety, fatigue and pain impact and to con-
tribute to improvements in levels of quality of life, sleep
difficulties, MS illness acceptance, active coping skills,
social support and resilience (secondary outcomes) in
those newly diagnosed with MS. Additionally, the pilot
trial aimed to assess the adherence and acceptability
among participants (tertiary outcomes) of the tailored
CBT program for individuals with MS. The tailored
CBT intervention lends from Beck’s cognitive theoretical
model for the treatment of depression in adults. Partici-
pants were given homework to complete for each of the
8 sessions. All sessions (apart from the first session
which was 1.5 h) were 1 h in duration and took place in
a clinic room at the hospital. A senior clinical psycholo-
gist and a provisional clinical psychologist (supervised
by the clinical psychologist) provided the intervention.
The CBT intervention consisted of 8 individual mod-
ules which focused on CBT based principles and strat-
egies. These strategies included progressive muscle
relaxation, controlled breathing exercises, pleasant activ-
ity scheduling, problem solving skills, cognitive exercises
which helped individuals identify, challenge and manage
unhelpful thoughts and beliefs. For the intervention, a
therapy manual was developed by the first author, which
included tailored modules and skills for MS patients.
Relevant and targeted treatments have been found to be
more effective and preferred over generic CBT interven-
tions among individuals with MS [18]. MS specific issues
such as addressing grief over MS-related losses and use
of relevant examples during therapy were included in
the tailored program. The intervention also focused on
facilitating acceptance of MS illness and adjusting to liv-
ing with MS and the final therapy session was dedicated
to relapse prevention.
Treatment as usual (TAU)
Participants in the TAU group did not obtain any psy-
chological treatment for depressive symptoms or anxiety
for the entire length of their involvement in the trial
(20 weeks) and received usual medical care from their
neurologist which may include 1–3 visits for medication
review during the course of involvement in the current
trial. All participants were offered the tailored CBT
intervention after completion of their involvement in the
TAU arm and 2 participants took up this offer.
Outcome measures
Demographic and medical data
Demographic data (age, gender, level of education, em-
ployment status, marital status, ethnic background); MS
data (MS type, months since first MS symptoms, current
disease modifying medication); mental health data (anti-
depressant medication use, previous diagnosis of depres-
sion and anxiety disorder); and level of ambulation was
measured using the ambulation questions from the self-
report Expanded Disability Status Scale (EDSS) [29] were
collected from each participant at baseline.
Primary outcome measure
Level of depression
The primary outcome was level of depressive symptoms
at post and 3 month follow up which was measured with
the Beck Depression Inventory-II (BDI-II) [26]. Cron-
bach’s α in this sample was excellent (.90).
Secondary outcome measures
Level of anxiety
Anxiety was measured with the 20-item State Trait Anx-
iety Inventory (STAI) [30]. The STAI evaluates feelings
of tension, nervousness, worry and apprehension ‘in the
past two weeks, including today’ with higher scores
reflecting higher severity. In the current sample, the
STAI showed excellent reliability (a = .95).
Fatigue impact
The 5-item Modified Fatigue Impact Scale (MFIS-5) [31]
was used to measure fatigue impact. Higher scores indi-
cate greater impact of fatigue on physical, cognitive and
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psychosocial functioning. Cronbach’s α in this sample
was excellent (.84).
Pain impact
The Pain Effects Scale (PES) [31] was used to measure the
level of impact that pain had on mood and behavior. Higher
scores indicate a greater impact of pain on a patient’s mood
and behavior. Cronbach’s α in this sample was (.91).
MS related quality of life
The Multiple Sclerosis Quality of Life (MSQOL-54) [32]
was used to measure MS related quality of life. Two
summary scores, physical health and mental health, can
be derived from a weighted combination of scale scores.
Higher scores indicate higher quality of life. Cronbach α
for the scale was .95.
Sleep quality
The 9-item Pittsburgh Sleep Quality Index (PSQI) [33]
was used to examine sleep quality, sleep latency, sleep
duration, habitual sleep efficiency, sleep disturbances,
use of sleep medication, and daytime dysfunction over
the last month. An overall score of 5 or more indicates a
‘poor’ sleeper. Cronbach’s α for this scale was .74.
Coping
The 66-item Ways of Coping Questionnaire (WCQ) [34]
was used to examine coping which consists of eight
scales measuring confrontive coping, distancing, self-
controlling, seeking social support, accepting responsi-
bility, escape-avoidance, planful problem-solving, and
positive reappraisal. Higher scores indicating greater use
of the coping strategy. Cronbach’s α for the entire scale
was .94.
Acceptance of MS illness
The 10-item Acceptance of Chronic Health Conditions
Scale (ACHC) [35] was used to measure acceptance of
MS illness which has been adapted to be used with an
MS population. Lower scores reflect higher levels of ac-
ceptance. Cronbach’s α in this sample was .86.
Level of social support
The 12-item Perceived Social Support Scale (PSSS) [36]
assesses perceived social support from family, friends,
and others. Higher scores indicated higher perceived
social support. Cronbach’s α in this sample was .94.
Level of resilience
The 33-item Resilience Scale for Adults (RSA) [37] was
used to measure level of resilience and investigates five
main protective factors: personal competence, social
competence, personal structure, family cohesion and
social resources. Higher scores indicate higher levels of
resilience. Cronbach’s α in this sample was .93.
Level of therapeutic alliance
Therapeutic alliance was measured using the 19-item
Helping Alliance Questionnaire-Version 2 (patient ver-
sion) (HAQ-II) [38]. The HAQ-II total score ranges
from 19 to 114, with higher scores indicating stronger
patient-therapist therapeutic alliance. The cut-off point
to indicate good therapeutic alliance is a score of 86 or
higher [38]. Cronbach’s α for the scale was .93.
Acceptance of the CBT based intervention
A 5-item questionnaire was developed by the first author
to assess how useful and acceptable the tailored CBT
intervention was using the following questions: ‘Approxi-
mately what proportion of the handouts have you read?’
and ‘How useful has this treatment course been for you?’,
‘What were the best and worst aspects of this treatment’
and ‘How could this treatment be improved?’
Patient satisfaction questionnaire
An 18-item questionnaire was designed by the first au-
thor to assess participants’ satisfaction with the CBT
intervention. The questionnaire asked about: the num-
ber of sessions completed and whether these met their
needs and expectations, the timing and content of ses-
sions, perceived benefits of the skills taught in the inter-
vention including the management of depressive and
anxiety symptoms, identifying unhealthy thinking styles,
pleasant activity scheduling, mood and anxiety monitor-
ing, challenging negative thoughts, controlled breathing
and relaxation exercises, fatigue management, sleep hy-
giene, problem solving skills and relapse prevention. Par-
ticipants were also asked whether they would
recommend this intervention to a close friend in the
same situation.
Statistical analyses
Statistical analyses were performed using SPSS version
22 for Windows. To examine group differences at base-
line individual analyses of variance (ANOVAs) were per-
formed with all outcome variables. To examine group
differences at post and 20 week follow up assessment,
individual analyses of covariance (ANCOVAs) were per-
formed with baseline treatment outcome scores used as
the covariate. Effect sizes from pre to post and pre to
follow up were calculated using Cohen’s d for each out-
come measure. All statistical analyses included a sample
of 30 participants at pre, post and 20 weeks follow up
and were undertaken controlling for gender and ambula-
tion status.
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Results
Participants
Table 1 shows the characteristics of participants. The
groups were well matched on all demographic and med-
ical variables. All participants had relapse remitting MS
and were able to walk independently without an aid.
Participants were most commonly female, employed, ter-
tiary educated, in a stable relationship, and receiving disease
modifying medication. Half of the participants have been
previously diagnosed with depression and almost half have
previously been diagnosed with an anxiety disorder.
Analysis of primary outcomes
Results of ANCOVAs examining group differences on
primary and secondary variables at pre, post and 20 week
follow up are presented in Table 2. There were no sig-
nificant differences across the groups on demographic
characteristics or significant differences on baseline
levels of the primary and secondary outcome measures.
Linear models revealed that those in the CBT group,
when compared to the TAU group, had significantly
lower scores on the BDI-II at post and at 20 week follow
up (ds ranging from 1.34 to 1.66).





Age (M, SD) 34.60 (9.06) 39.27 (9.93)
Time since diagnosis in months (M, SD) 26.20 (15.58) 23.53 (16.06)
Months since first MS symptoms (M, SD) 35.54 (16.47) 30.57 (18.68)
Gender (n)% female (13) 86.7% (9) 60%
Years of education (n)%
Secondary (4) 26.7% (3) 20%
Trade, Tafe or Diploma (4) 26.7% (4) 26.7%
Undergraduate (3) 20% (2) 13.3%
Postgraduate (4) 26.7% (6) 40%
Employment status (n)%
Unemployed (4) 27% (5) 33.3%
Part time (4) 27% (4) 27%
Full time (7) 47% (6) 40%
Marital status (n)%
Single (2) 13% (0) 0%
Partnered/Married (13) 86.6% (15) 100%
Ethnic background (n)%
Australian (11) 73% (10) 66.6%
Other (4) 26.6% (5) 33.3%
Ambulation status (n)%
Able to walk independently without aid (15) 100% (15) 100%
MS type (n) %
Relapse remitting (15) 100% (15) 100%
Currently taking MS disease modifying medication
Yes (n)% (12) 80% (10) 66.7%
Currently taking antidepressant medication
Yes (n)% (6) 40% (5) 33.3%
How long on this medication in months (M, SD) 24.33 (20.68) 25.20 (15.53)
Previously diagnosed with depression
Yes (n)% (8) 53.3% (7) 46.7%
Previously diagnosed with anxiety
Yes (n)% (6) 40% (6) 40%
M Mean, SD standard deviation, TAU Treatment as usual control group
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Table 2 Results of ANCOVAs examining group differences on primary and secondary variables at pre, post and 20 week follow up
Pre Post Pre to post 20 week fup Pre to fup
Variable Mean (SD) Mean (SD) F (df = 1,29) d (95% CI) Mean (SD) F (df = 1,29) d (95% CI)
BDI-2
CBT 29.80 (11.40) 10.89 (6.19) 9.33 (7.89)
TAU 28.53 (12.21) 25.40 (10.31) 29.17*** 1.66 (0.83, 2.49) 24.34 (13.54) 18.43*** 1.34 (0.54, 2.13)
STAI
CBT 45.40 (6.26) 33.87 (6.88) 36.20 (10.77)
TAU 48.86 (11.20) 50.46 (12.22) 28.67*** 1.63 (0.80, 2.45) 45.67 (14.15) 2.95 0.73 (− 0.01, 1.47)
MFIS
CBT 12.13 (3.58) 8.73 (3.58) 8.06 (3.03)
TAU 12.26 (3.84) 11.93 (4.38) 5.89* 0.78 (0.04, 1.52) 11.06 (4.74) 11.16** 0.73 (− 0.01, 1.47)
PES
CBT 17.06 (5.62) 12.53 (6.18) 11.26 (4.51)
TAU 18.80 (6.57) 17.67 (7.05) 3.92* 0.75 (0.01, 1.49) 16.80 (5.91) 9.80** 1.03 (0.26, 1.79)
MSQOL mental
CBT 36.06 (14.81) 63.13 (14.42) 69.93 (19.64)
TAU 40.06 (17.35) 44.20 (21.05) 12.73*** 1.03 (0.26, 1.79) 49.27 (20.49) 12.28** 1.00 (0.24,1.76)
MSQOL physical
CBT 47.39 (18.07) 65.92 (14.66) 63.32 (17.25)
TAU 43.28 (17.63) 47.74 (19.07) 18.26*** 1.04 (0.28, 1.80) 49.33 (21.32) 7.85** 0.70 (−0.03, 1.44)
PSQI
CBT 9.00 (3.46) 4.40 (2.09) 4.80 (2.54)
TAU 9.06 (3.93) 7.87 (2.99) 22.02*** 1.31 (0.52, 2.10) 8.20 (3.60) 11.06** 1.06 (0.30,1.83)
PSSS
CBT 63.73 (16.41) 59.46 (13.45) 62.26 (20.39)
TAU 69.40 (12.10) 57.33 (12.48) 15.51** 0.96 (0.20, 1.71) 58.86 (17.31) 0.001 0.17 (−0.54, 0.89)
RSA
CBT 137.29 (34.38) 165.45 (26.30) 164.10 (25.95)
TAU 146.40 (32.38) 148.25 (32.63) 17.98*** 0.57 (−0.16, 1.30) 149.53 (37.84) 8.49** 0.44 (−0.29, 1.16)
Acceptance
CBT 30.40 (6.04) 28.20 (3.89) 27.93 (3.88)
TAU 32.13 (4.82) 31.14 (4.78) 2.18 0.66 (−0.09, 1.41) 31.40 (5.96) 3.01 −0.67 (−1.39,0.08)
Problem solving
CBT 6.76 (3.19) 8.87 (3.54) 8.93 (3.53)
TAU 6.73 (4.10) 8.73 (4.31) 0.09 −0.46 (−1.19,0.26) 6.81 (3.97) 3.99* 0.55 (−0.18,1.28)
Avoidance
CBT 9.87 (4.99) 4.20 (3.07) 3.93 (2.96)
TAU 8.53 (5.22) 7.40 (4.45) 11.27** 0.81 (0.05, 1.53) 7.87 (5.24) 9.75** 0.90 (0.13, 1.62)
FU 20 week follow up, ns not significant, CBT tailored CBT intervention, TAU treatment as usual, BDI Beck Depression Inventory –II, STAI State Trait Anxiety
Inventory, MFIS Modified Fatigue Impact Scale, PES Pain Effects Scale, MSQOL mental Multiple Sclerosis Quality of Life-mental health summary score, MSQOL phys-
ical Multiple Sclerosis Quality of Life-physical health summary score, PSQI Pittsburgh Sleep Quality Index, PSSS Perceived Social Support Scale, RSA Resilience Scale
for Adults, Acceptance Acceptance of Chronic Health Conditions Scale, Problem solving Ways of coping questionnaire – planful problem-solving subscale, Avoidance
Ways of coping questionnaire – escape-avoidance subscale
*p < .05, **p < .01; ***p < .001
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Analysis of secondary outcomes
Linear models revealed that those in the CBT group
were associated with lower post intervention and 20 week
follow up STAI scores (ds ranging from 0.73 to 1.63) al-
though this was not statistically significant (F(1, 29) =
2.95, p > 0.05) compared to the TAU group. There were
significant group differences on the MFIS and PES
scores at post (ds ranging from 0.75 to 0.78) and 20 week
follow up (ds ranging from 0.73 to 1.03) with the CBT
group showing significantly greater reductions on scores
on both scales.
There were significant group differences on the MSQOL
physical health composite score at post and at 20 week
follow up (ds ranging from 0.70 to 1.04) and the MSQOL
mental health composite score at post and at 20 week
follow up (ds ranging from 1.00 to 1.03) with the CBT
group showing significantly greater improvements on both
scales. There was also a significant group difference on
the RSA at post and at 20 week follow up (ds ranging
from 0.44 to 0.57). Specifically, there were significant
group differences on the RSA subscale of personal
competence at post (F(1, 29) = 10.54, p < 0.001) and 20 week
follow up (F(1, 29) = 8.20, p < 0.01) and on the RSA sub-
scale of social resources at post (F(1, 29) = 17.97, p < 0.001)
and at 20 week follow up (F(1, 29) = 7.70, p < 0.01).
There were significant group differences on the PSQI
score at post and at 20 week follow up (ds ranging from
1.06 to 1.31). There were also significant group differ-
ences on the PSSS score at post and at 20 week follow
up (ds ranging from 0.17 to 0.96). Compared to the TAU
group, those in the intervention showed more MS diag-
nosis acceptance although this was not statistically sig-
nificant. Those in the CBT group also reported
significantly lower escape avoidance coping at post and
at 20 week follow up and significantly higher planful
problem solving coping at 20 week follow up (ds ranging
from −0.46 to 0.90). No other group differences were
found for the other coping styles.
Acceptance and satisfaction with the intervention
All participants in the intervention (n = 15) reported
having a very strong therapeutic alliance with the psych-
ologist (X = 102.33, SD = 9.59). All participants in the
CBT intervention reported reading and completing all of
the materials provided for homework and reported that
the intervention was ‘very useful’, that all of the 8 inter-
vention sessions were ‘much to very much’ useful and
beneficial, that they would ‘definitely’ recommend the
intervention to a close friend who had MS and that the
early intervention should be offered as part of routine
care straight after diagnosis. The majority of participants
(12/15, 80%) reported that the intervention contained
‘enough sessions’, that they would like ‘more sessions if
they experienced new problems’, that the intervention
addressed their problems ‘completely’ (11/15, 73.4%) and
that the sessions were ‘completely- to a large extent’ (11/
15, 73.4%) as they expected them to be. Just over half of
the participants reported that the intervention came ‘at
the right time’ for them (8/15, 53.3%) with the other half
of participants reporting that it ‘could have even been of-
fered earlier’ (7/15, 46.7%).
Discussion
This study demonstrated that a tailored 8-week individ-
ual face-to-face CBT based intervention was effective in
significantly reducing depressive symptoms in patients
newly diagnosed with MS. The data suggests that those
participants in the CBT intervention reported significant
reductions in levels of depressive symptoms. The be-
tween group effect sizes for the BDI-II at the end of
treatment was 1.66 and 1.34 at 20 weeks follow up
which were well above the 0.80 cut-off for a large treat-
ment effect [39]. In addition, those in the CBT group re-
ported significant reductions in level of anxiety, fatigue
and pain impact on physical, cognitive and psychosocial
functioning and escape avoidance coping and significant
increases in MS related quality of life in both the mental
and physical domains, MS illness acceptance, sleep qual-
ity, level of resilience in particular the personal compe-
tence and social resources domains, perceived social
support and planful problem solving coping at both post
and at the 20 week follow up assessment. The between
group effect sizes at post treatment (range between 0.57
and 1.63) and at 20 weeks follow up (range between 0.44
and 1.06) strongly supported the benefits of early
intervention.
Individuals in the CBT intervention reported being
satisfied with the tailored 8-week intervention and ad-
hered to the therapy. All participants found the inter-
vention ‘acceptable’ and ‘very useful’. All participants
reported that the intervention was timely, that it ad-
dressed their problems ‘completely’, met their expecta-
tions ‘completely and to a large extent’, that all materials
and strategies based on CBT principles contained in all
sessions were ‘much-very much’ useful and beneficial. Of
note, participants indicated that the CBT intervention
should be offered as part of routine care to everyone
who is newly diagnosed with MS. Adherence data sug-
gested that all participants in the CBT intervention com-
pleted all of the 8 modules including all the readings
and homework and there were no drop outs suggesting
individuals were self-motivated to receive the treatment.
All participants also reported a strong therapeutic alli-
ance with their therapist.
Strengths and limitations
This research has several strengths. First, this study used a
randomized, controlled pilot intervention design with
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clearly defined outcomes, and to the best of our knowledge,
the first study to test an early tailored CBT intervention for
the treatment of depressive symptoms in individuals who
are within five years of being diagnosed with MS. Second,
the research was conducted within a large MS clinic in a
hospital service increasing the likelihood that the findings
may be applicable to a wider MS population. Third, the
sample was homogenous in terms of age, level of ambula-
tion, length of MS diagnosis, MS type, education level and
marital status. There were some limitations to this research.
As a preliminary pilot study, it had a small sample size.
Only two therapists conducted the CBT intervention. The
majority of the study sample was educated and employed
which may limit the generalizability of the results. The
study mostly relied on self-report measures and as such
there is a chance that participants may under or over report
their symptoms. The current study did not compare the
CBT intervention to an active comparative intervention.
Future research should consider comparing the current
treatment to a supportive counselling intervention which
may control for non-specific therapeutic effects such as
time and attention from a caring health professional. This
will help to determine whether the specific components
included in the CBT intervention are more effective in
treating depression and resulting in broader based improve-
ments or whether the therapeutic elements of seeing a
psychologist, participating in a research study or coming in
for regular appointments are just as effective in producing
these improvements in those newly diagnosed with MS.
The assessment period was limited to 3 months and it is
not known if the benefits are sustained or if further ‘top up’
therapy is required. Larger studies with extended follow up
and adequate disease measures are required in order to de-
termine if the current intervention can impact disease pro-
gression. Monitoring of treatment fidelity (treatment
implementation) was not done by an independent rater and
no audio recordings of therapy sessions were undertaken
which did not allow for therapist competency ratings. Also
there were only two clinical psychologists who undertook
all assessments and provided the intervention. In addition,
future trials should include blinding of psychologists
undertaking assessments and those providing the
intervention and have separate people involved with
the generation and allocation concealment, enrollment
of participants and implementation and monitoring of
the intervention. Further studies are required to assess
the cost effectiveness and efficacy of the tailored CBT
intervention among larger samples in order to pro-
mote it as part of routine care for individuals newly
diagnosed with MS.
Conclusion
The current preliminary results provide novel evidence
for the benefits of early intervention for the treatment of
depressive symptoms in patients newly diagnosed with
MS. The tailored early CBT intervention was found to be
an acceptable and effective treatment for depression in a
sample of individuals newly diagnosed with MS within a
hospital outpatient facility. It also had broader benefits
on anxiety, fatigue and pain management, MS illness
acceptance, sleep quality, MS related quality of life,
coping, resilience and social support in these individuals.
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